TET2 and diffuse large B-cell lymphoma: However, in diffuse large B‐cell lymphoma (DLBCL), Tanager and colleagues confirmed that although most tumors showed a reduction in 5hmC, only approximately half harboured mutations in epigenetic regulators such as TET2 and DNMT3A.